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Li-Fraumeni syndrome (LFS) is a prototypical cancer predisposing syndrome first described in 1969 by Drs. Frederick Li and Joseph Fraumeni following their retrospective analysis of children with rhabdomyosarcoma (RMS) (Li & Fraumeni, 1969a,b) . Since their initial report, many studies by these and other investigators have revealed that LFS is a rare autosomal dominant disorder that confers an increased risk to develop six common 'core' cancers, including soft tissue sarcomas (STS), osteosarcoma (OS), premenopausal breast cancer, central nervous system (CNS) tumours, adrenocortical carcinoma (ACC) and leukaemia (Malkin et al, 1990) . A wide spectrum of other benign and malignant neoplasms is also observed (Nichols et al, 2001) .
A breakthrough in the understanding of LFS occurred in 1990 when Malkin et al (1990) demonstrated that individuals with LFS harbour germline mutations in TP53 the gene encoding the TP53 transcription factor (tumor protein p53, TP53; previously termed p53). Also known as the 'guardian of the genome', TP53 plays a central role in cellular growth control by regulating the expression of numerous downstream genes involved in cell cycle arrest, apoptosis, DNA repair and senescence, particularly in response to DNA damage and other cellular stressors (Vousden & Prives, 2009; Reinhardt & Schumacher, 2012) . TP53 was examined as an LFS candidate gene based on observations that somatic TP53 mutations were prevalent in the majority of human cancers, including those seen in LFS . Furthermore, transgenic mice expressing mutant Trp53 alleles developed LFS-type cancers, including OS, STS and lymphoid neoplasms (Lavigueur et al, 1989) . A heterozygous germline TP53 mutation was identified in each of the five families analysed by Malkin et al (1990) , and in one family, the mutation co-segregated with tumour formation. At the same time, an unrelated kindred harbouring a germline TP53 mutation was reported by Srivastava et al (1990) . Taken together, these formative observations confirmed that mutations in TP53 occur not only as common somatic events in cancer, but also as rare germline events in individuals with LFS.
The spectrum of cancers observed in LFS
One of the most striking features of LFS is the remarkable tendency for affected individuals to develop solid and haematological cancers. The risk for germline TP53 mutation carriassociated hereditary breast cancer, which can affect men as well as women, breast cancer appears to occur exclusively in women with LFS (Malkin, 1994) . In female germline TP53 mutation carriers, the breast cancer risk increases at approximately 20 years of age and continues into adulthood, with the median age of breast cancer onset being 33 years (Sorrell et al, 2013; Bougeard et al, 2015) . Consistent with this finding, 3-8% of women with apparently sporadic breast cancer who present under the age of 30 years harbour a germline TP53 mutation (Mouchawar et al, 2010; McCuaig et al, 2012) . Many LFS-associated breast cancers exhibit oestrogen and progesterone receptor positivity, and HER2/neu amplification (Masciari et al, 2012; Melhem-Bertrandt et al, 2012; Bougeard et al, 2015) . Malignant phyllodes tumours, uncommon fibroepithelial lesions of the breast, are also infrequently reported Villani et al, 2016) .
Together, STS and OS comprise 25-38% of LFS-related malignancies (Gonzalez et al, 2009a; Ognjanovic et al, 2012) and are the most common cancers in children and adolescents. The prevalence of STS has been reported to range from 17Á8% to 27%, while OS has a slightly lower prevalence of 13Á4-16% (Bougeard et al, 2015) . RMS often occurs before the age of 5 years (Diller et al, 1995; Ognjanovic et al, 2012; Hettmer et al, 2014) and OS before the age of 30 (Mirabello et al, 2015) . In a study of 15 children with non-alveolar anaplastic RMS, Hettmer et al (2014) found that all five children diagnosed under 3 years of age, and six of eight (75%) diagnosed between 3 and 7 years of age, harboured a germline TP53 mutation. Thus, children with non-alveolar anaplastic RMS, or individuals with early onset OS warrant consideration for LFS, particularly if there is a positive family history of cancer. Other STS are rarely encountered, including, liposarcoma, leiomyosarcoma and several less well defined subtypes .
Neoplasms of the CNS account for 9-14% (Gonzalez et al, 2009a; Sorrell et al, 2013; Bougeard et al, 2015) of LFS tumours with the most common type being glioblastoma/astrocytoma. Medulloblastoma, ependymoma, supratentorial primitive neuroectodermal tumours and choroid plexus carcinomas (CPC) are also reported (Sorrell et al, 2013) . The age of onset of CNS cancers is biphasic with the first peak in childhood and a second peak at 20-40 years of age (median (Ribeiro et al, 2000) ACC harbouring somatic ATRX mutations are larger, more likely to be advanced stage and associated with a poorer prognosis (Pinto et al, 2015) Breast cancer 27-31% (Gonzalez et al, 2009a; Id Said et al, 2016) Pre-menopausal women (33 years) (Olivier et al, 2003) Invasive ductal carcinoma commonly ER and PR positive and/or HER2/neu amplified (Masciari et al, 2012; Melhem-Bertrandt et al, 2012; Bougeard et al, 2015) CNS tumour (choroid plexus carcinoma, medulloblastoma, gliomas)
9-14% (Gonzalez et al, 2009a; Bougeard et al, 2015; Wasserman et al, 2015; Id Said et al, 2016) Biphasic with first peak in childhood and second peak at 20-40 years of age (Palmero et al, 2010) (16 years) (Olivier et al, 2003; Tabori et al, 2010; McBride et al, 2014) Medulloblastoma of Sonic hedgehog subtype (SHH) (Zhukova et al, 2013) and presence of chromothripsis Soft tissue sarcomas (rhabdomyosarcoma)
17Á8-27% (Bougeard et al, 2015; Id Said et al, 2016) Prior to age 5 years (Olivier et al, 2002; Palmero et al, 2010 ) (3Á6 years) (Hettmer et al, 2014) Non-alveolar, anaplastic rhabdomyosarcoma (Hettmer et al, 2014) , mostly embryonal rhabdomyosarcoma (ERMS) Osteosarcoma 13Á4-16% (Bougeard et al, 2015; Id Said et al, 2016) Prior to age 18 years in children (14 years). Few reported cases in adults up to age 55 years (Bougeard et al, 2015) No clear phenotypic differences between OS occurring in individuals with LFS versus those without LFS Leukaemia 2-4% (Gonzalez et al, 2009a; Bougeard et al, 2015) Children and young adults (12 years) (Bougeard et al, 2015) Hypodiploid phenotype (Pui et al, 1987; Nachman et al, 2007; Holmfeldt et al, 2013; Malkin et al, 2014) ACC, adrenocortical carcinoma; CNS, central nervous system; ER, oestrogen-receptor; LFS, Li-Fraumeni syndrome; OS, osteosarcoma; PR, progesterone receptor.
16 years) (Olivier et al, 2003; Tabori et al, 2010; McBride et al, 2014) . There is a strong relationship between LFS and CPC, with up to 100% of children with CPC harbouring a germline TP53 mutation, regardless of whether or not there is also a positive family history of cancer (Krutilkova et al, 2005; Gonzalez et al, 2009a; Tabori et al, 2010) . Among children with medulloblastoma, those with aberrant activation of the Sonic Hedgehog pathway are most likely to harbour germline TP53 mutations (Zhukova et al, 2013) as are those whose tumours contain somatic TP53 mutations or evidence of chromothripsis (catastrophic DNA rearrangements) (Rausch et al, 2012; Zhukova et al, 2013) . Adrenocortical carcinoma adevelops in 6-13% (Kleihues et al, 1997; Gonzalez et al, 2009a; Bougeard et al, 2015; Mai et al, 2016) of LFS patients with a bi-modal age distribution peaking before 5 years of age and again in the fourth to fifth decades of life. Studies of children with what appears to be sporadic ACC reveal a 30-80% prevalence of germline TP53 mutations (Wagner et al, 1994; Libe & Bertherat, 2005; Pinto et al, 2015; Wasserman et al, 2015) . The R337H TP53 founder mutation (see below, Genotype-Phenotype Correlations), which is present in up to 0Á3% of the Southern Brazilian population, is well-recognized to be associated with the development of ACC in Brazilian children (Ribeiro et al, 2001; Custodio et al, 2012) .
Leukaemia, including acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), exhibit a prevalence of 2-4% in germline TP53 mutation carriers (Gonzalez et al, 2009a; Ruijs et al, 2010; Bougeard et al, 2015) . Lymphoma occurs slightly less often, with a prevalence of 2% (Bougeard et al, 2015) . The median age of onset is 12 (range 2-35) for leukaemia and 13 years (range 2-42) for lymphoma (Bougeard et al, 2015) . There is a paucity of published literature detailing the AML, MDS and lymphoma subtypes that occur in individuals with LFS. However, when ALL occurs in the context of LFS, it often exhibits a pre-B cell 'low' hypodiploid phenotype in which the leukaemic cells contain 32-39 chromosomes, although other ALL subtypes have also been described (Holmfeldt et al, 2013; Malkin et al, 2014) . In a large genomic profiling study involving 124 cases of childhood hypodiploid ALL, Holmfeldt et al (2013) reported that approximately 91Á2% of the low hypodiploid samples exhibited somatic TP53 mutations, the majority of which were homozygous as a result of loss of the wild-type TP53 allele. Remarkably, almost half of the studied cases demonstrated presence of the same TP53 mutations within non-tumour cells, suggesting that these were germline alterations. Zhang et al (2015) also described that 19% of children with hypodiploid ALL harbour germline TP53 mutations. In the report by Holmfeldt et al (2013) , somatic TP53 mutations were also observed in 10 of 11 (90Á9%) low hypodiploid ALL samples obtained from adult patients; however, none had evidence of a germline TP53 mutation. Together, these findings suggest that TP53 mutations are a hallmark of the low hypodiploid phenotype and that paediatric, but not adult low hypodiploid, ALL may be considered a rare manifestation of LFS.
To date, one family presenting with leukaemia as a primary manifestation of LFS has been reported. Powell et al (2013) described a Hispanic kindred in which five individuals were diagnosed with leukaemia. One case of ALL exhibited doubling of a hypodiploid clone; the cytogenetic findings related to the other cases was not discussed. Exome sequencing of this kindred revealed a p.R306X germline mutation, which has been previously identified in both somatic and germline samples, generally in association with the more typical cancers seen in LFS. The unique leukaemia predilection in this kindred suggests the potential existence of an as yet unidentified genetic modifier associated with the development of haematopoietic cancers in the TP53 mutation carriers in this family (Powell et al, 2013) .
In addition to the core cancers, LFS patients develop additional malignancies, many of which occur at earlier than expected ages, including colorectal, lung, pancreatic, melanoma, prostate, kidney, testicular, laryngeal, head and neck and ovarian cancers (Varley et al, 1997; Chompret et al, 2000; Nichols et al, 2001; Olivier et al, 2003; Wong et al, 2006; Gonzalez et al, 2009a; Ruijs et al, 2010) .
LFS and the risk for second primary and therapy-associated cancers
Li-Fraumeni syndrome patients are more likely to develop multiple primary and therapy-related cancers, a proportion of which are haematological. Among 200 patients from 24 LFS kindreds reported by Hisada et al (1998) , 30 (15%) developed a second cancer, eight (4%) a third cancer and four (2%) a fourth cancer. In this study, the relative risk of occurrence of a second cancer was 5Á3 times greater than that of the general population, with a cumulative probability of second cancer development of 57% at 30 years following the diagnosis of a first cancer. Remarkably, the relative risk of a second cancer was 83-times higher for individuals with LFS who developed a first cancer during childhood. Mai et al (2016) recently reported similar results where about 49% of germline TP53 mutation carriers with a first cancer developed at least one other cancer after a median time period of 10 years.
Data describing the factors contributing to development of therapy-related cancer in LFS are limited; however, it is probable that these partly result from the carcinogenic effects of the radiation (RT) and/or chemotherapy used to treat the previous cancer(s). Findings supporting this notion include laboratory data in which RT-treated fibroblasts from LFS patients exhibit compromised cell cycle arrest and increased chromosomal aberrations compared to wild-type fibroblasts (Boyle et al, 2001; De Moura et al, 2010) . Following a single exposure to 1 or 4 Gy of irradiation, Trp53 heterozygous mice exhibit a marked reduction in tumour latency when compared to wild-type Trp53 animals (Kemp et al, 1994) . Consistent with these findings, several case reports and small case series describe an increased prevalence of solid cancers in LFS patients who receive RT versus those who do not, with some tumours arising within the radiation field (Heymann et al, 2010; Pierce & Haffty, 2011) . Despite these observations, little remains known about the true prevalence of RT-induced cancers, as well as their relationship to radiation dose, age at treatment with RT, and/or the tissue being radiated.
Germline TP53 mutations may also contribute to therapyassociated leukaemias and MDS. Towards this end, a study of 53 patients with therapy-associated myeloid neoplasms revealed four (7Á5%) harboring germline TP53 mutations (Schulz et al, 2012) . Similarly, a study of 47 breast cancer survivors with secondary leukaemia identified three (6%) individuals with germline TP53 alterations (Churpek et al, 2016) . In the latter study, two of these three individuals developed ALL, an unusual treatment-related haematopoietic malignancy. Compared to primary ALL developing in children with germline TP53 mutations, these two cases of presumed therapy-related leukaemia did not exhibit a hypodiploid phenotype. Hence, for cancer patients who develop secondary ALL, regardless of its cytogenetic makeup, consideration should be given to germline TP53 testing (for further discussion see below, Clinical Management).
The TP53 gene and its encoded protein TP53 is located at chromosome 17p13.1 and spans approximately 20 kb of genomic DNA. It is composed of 14 exons including ten that encode the full length 393-amino acid TP53 protein, one non-coding exon (exon 1) and three alternative exons (exons 2/3, 9b, 9c) (Hainaut & Pfeifer, 2016) . The TP53 functional domains consist of an N-terminal transcriptional activation domain, proline-rich region, DNA binding domain, tetramerization domain and C-terminal regulatory domain (Fig 1) (Beckerman & Prives, 2010) . It was initially proposed that TP53 functioned as an oncogene given the finding that many tumours expressed increased levels of the TP53 protein (Rotter, 1983; Eliyahu et al, 1984) .
However, Baker et al (1989) showed that there was mutational inactivation of one TP53 allele with loss of the second wild-type allele in two colorectal cancers studied. Around this time, Finlay et al (1989) demonstrated that oncogenedriven cellular transformation could be inhibited by forced expression of wild-type TP53. Collectively these and other observations revealed that TP53 served as a tumour suppressor and not as an oncogene as originally proposed.
In unstressed cells, TP53 levels are kept low via a negative-regulatory feedback mechanism mediated by the E3 ubiquitin ligase Mouse Double Minute 2 homolog (MDM2), whose expression is induced by TP53. MDM2 binds to the N-terminal domain of TP53 and covalently attaches ubiquitin, thus marking TP53 for degradation by nuclear and cytoplasmic proteasomes (Fig 2) . Accordingly, in normal cells, TP53 is very unstable, with a half-life ranging from 5 to 30 min (Moll & Petrenko, 2003) . Following exposure to genotoxic stressors, such as ionizing radiation, oxidative stress and nucleotide depletion, TP53 and MDM2 become phosphorylated. As a result, the MDM2-TP53 interaction is weakened. This weakening lessens TP53 degradation, allowing TP53 to accumulate, self-associate and bind to specific DNA sequences. Functional TP53 tetramers then induce the expression of numerous downstream target genes that regulate critical cellular processes, such as cell cycle arrest, apoptosis and DNA repair.
The role of TP53 in the haematopoietic compartment
The haematopoietic compartment exhibits a remarkable and dynamic capacity for regeneration. Under normal conditions, haematopoietic stem cells (HSC), the precursors from which all blood cells arise, remain quiescent with only a small fraction entering the cell cycle and giving rise to differentiating progenitors that replenish cells that are lost due to normal processes, such as aging. In contrast, under conditions of stress, such as trauma or exposure to cytotoxic therapies, HSC must proliferate to maintain and/or expand their pool while replacing those cells that are actively damaged or lost. Within the haematopoietic compartment, TP53 is mainly expressed in HSC, where it is essential for maintaining HSC quiescence, self-renewal and genomic integrity (Asai et al, 2011; Pant et al, 2012) . Evidence for the importance of TP53 in HSC quiescence comes from the study of mice in which Trp53 or the genes encoding TP53 regulators such as Mdm2 have been deleted, overexpressed or mutated. Towards this end, Trp53-null HSC enter the cell cycle more readily than wild-type cells (Liu et al, 2009) . Consistent with these findings, Trp53-null mice exhibit a two-to three-fold increase in Lineage-Sca-1+ c-kit+ (LSK) cells (a bone marrow population containing HSC) as well as CD150 + CD48 À LSK, which are enriched for long term repopulating cells (Liu et al, 2009; Asai et al, 2011) . Additional proof that TP53 is important in HSC comes from bone marrow transplantation studies in which TP53-deficient bone marrow cells out compete TP53-expressing cells in competitive repopulation assays (Liu et al, 2009 ). Based on these findings, it has been suggested that the transient inhibition of TP53 function could be used to promote bone marrow recovery following chemo-or radiation therapy by allowing for increased HSC proliferation and/or selfrenewal. Indeed, small molecule inhibitors known as 'pififthrins' are under development for these purposes (Asai et al, 2011) .
In addition to its role as a regulator of HSC quiescence and self-renewal capacity, TP53 is important for regulating HSC 'fitness', where too little or too much TP53 activity can compromise the ability of HSC to repopulate the marrow. As noted above, Trp53-null HSC exhibit increased proliferative and short term repopulating capacity. Nonetheless, they are inferior to their Trp53-sufficient counterparts when it comes to long-term repopulation (Asai et al, 2011) . Similarly, too much TP53 is detrimental. The latter is made evident in mice with high basal levels of TRP53 activity, such as those harbouring additional copies of the Trp53 gene or animals haploinsufficient for the TP53 inhibitor Mdm2, which exhibit enhanced radiosensitivity and poor haematopoietic recovery following exposure to low levels of ionizing radiation. Collectively, these and other studies reveal that TP53 is a critical protein whose levels and activity must be carefully regulated within HSC to prevent leukemogenesis and promote homeostasis of the haematopoietic compartment under normal and stressful conditions (Asai et al, 2011; Pant et al, 2012) .
Mechanism by which TP53 contributes to tumour formation
There are several proposed mechanisms by which the mutant TP53 protein promotes tumour formation. These 
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(A) (B) Milner et al (1991) , where in vitro cotranslation of wild type and mutant TP53 enabled the formation of complexes containing both proteins. Willis et al (2004) provided further insights into the properties of these aberrant complexes. By examining the functions of cell lines expressing both wild-type and mutant TP53, these investigators demonstrated that the presence of mutant TP53 greatly reduced the ability of the wild-type protein to bind to promoters of TP53-responsive target genes. Indeed, the DN effect may explain why some TP53 mutation carriers exhibit retention of the wild-type TP53 allele within their tumours. Towards this end, Varley et al (1997) demonstrated that only 57% of tumours from patients with germline TP53 mutations showed loss of the wild-type allele and retention of the mutated allele. A subset of these patients was also analysed by Birch et al (1998) , who noted that all tumours that retained both TP53 alleles developed in individuals who harboured germline missense mutations within the DNA binding domain. This was in contrast to individuals harbouring null mutations, where loss of both alleles was invariably seen in the tumours (Birch et al, 1998) .
The GOF effect is characterized by acquisition of novel properties by mutant TP53 independent of the presence of the wild-type TP53 protein. Early evidence supporting the oncogenic function of mutant TP53 was derived from the observation that introduction of mutant TP53 into Trp53-null cells allowed for tumour outgrowth in mice. Cells completely devoid of TP53 form tumours that spontaneously regress. In contrast, cells expressing mutant TP53 exhibit lethal outgrowth (Wolf et al, 1984) . Brosh and Rotter (2009) elegantly review the properties by which mutant TP53 mediates the GOF effect. One key mechanism involves the inactivation of TP63/TP73 (p63/p73) proteins by mutant TP53; TP63 and TP73 are considered TP53-related proteins. When overexpressed, TP63/TP73 induce growth arrest and apoptosis in a TP53-like manner. Mutant TP53 binds to TP63/TP73 and aborts their ability to dampen cell proliferation and promote apoptosis. Another important mechanism involves the modulation of expression specific target genes by mutant TP53. Once such example includes transcriptional up regulation of the ATP binding cassette subfamily B member 1 gene (ABCB1; also termed multidrug resistance 1 gene, MDR1) by mutant TP53, which confers drug resistance to cancer cells harbouring somatic TP53 mutations (Chin et al, 1992) . Additional genes that are aberrantly regulated by mutant TP53 include NFKB1, MYC, EGR1 and TERT, among others (Brosh & Rotter, 2009) . Therefore, whereas wild-type TP53 regulates the expression of genes that mediate growth suppression, apoptosis and DNA repair, mutant TP53, through mechanisms that are not completely defined, regulates the expression of genes that enable cell proliferation, drug-resistance, survival and metastasis.
Regardless of the mechanism of action, mutations affecting TP53 perturb its many functions, leading to aberrant transcription, altered MDM2-TP53 interactions, mutant TP53 accumulation, deregulated cell cycle progression and impaired mechanisms of DNA repair (Fig 2) .
The spectrum of TP53 mutations in individuals with LFS
The distribution of TP53 germline mutations in LFS is similar those identified in tumours, with the majority clustered within the DNA binding domain where there are six recurrent 'hotspot' mutations involving codons 175 (R175H), 245 (G245S), 248 (R248Q, R248W), 273 (R273H) and 282 (R282W) (Wasserman et al, 2015) . Functional studies reveal that, among the mutations most commonly examined, the majority exerts a DN effect (Petitjean et al, 2007) . Mutations in intronic or regulatory regions are also reported; however, their functional significance remains to be elucidated. The International Agency for Research on Cancer (IARC) maintains a well-established repository of somatic and germline TP53 mutations. The current release (R18, April 2016, http:// p53.iarc.fr) includes 885 families harbouring 360 unique TP53 mutations. Among the germline TP53 mutations included, missense alterations constitute about 73%, nonsense 8Á89%, splice site 8Á16%, frameshift 5Á66%, silent 0Á55%, large deletions 0Á73%, intronic 0Á61% and other mutations (complex rearrangement, insertions, deletions) 2Á07%.
Genotype-phenotype correlations in LFS
In keeping with experimental data that not all TP53 mutants function equally, several genotype-phenotype studies involving LFS families have suggested that the type of germline TP53 mutation may serve as a predictor of tumour type and age of cancer onset. Birch et al (1998) examined 34 families meeting classic clinical criteria for LFS and observed that families harbouring missense mutations within the TP53 DNA binding domain had a more highly penetrant phenotype than families with other (nonsense or truncating) or no mutations. Most recently, Bougeard et al (2015) observed a significantly earlier age of tumour onset for patients with missense mutations (mean age of tumour onset 23Á8 years) compared to those with frameshift or in-frame deletions/insertions, nonsense mutations and genomic rearrangements (28Á5 years). The difference was even greater when missense mutations were compared to genomic rearrangements corresponding to extreme forms of null alterations (35Á8 years). Additionally, patients whose mutations were known to exert a DN effect exhibited an even earlier age at cancer onset (21Á3 years). Interestingly, ACC appear to be the only type of LFS-associated cancer consistently associated with germline mutations occurring outside the DNA-binding domain, with the majority of patients carrying mutations that are not dominant-negative missense mutations (Bougeard et al, 2015) .
The concept that different germline TP53 alterations confer variable oncogenic potential is further illustrated in the unique phenotype of carriers of the TP53 R337H mutation, which exhibits a high prevalence as a founder mutation in Southern Brazil (Ribeiro et al, 2001 ). This mutation is located within the tetramerization domain and was first identified by its strong association with an increased risk for childhood ACC. A recent study showed that among 292 children diagnosed with paediatric cancer in Southern Brazil, 11 (3Á7%) carried TP53 R337H, nine of whom were diagnosed with ACC and two with CPC (Giacomazzi et al, 2013) . The fact that none of the carrier parents in this study had cancer at the time of writing of this report suggested that the TP53 R337H mutation was associated with a lower penetrance compared to other germline TP53 mutations. Although initial reports suggested that the main cancer risk associated with the TP53 R337H mutation was the development of childhood ACC, more recent studies reveal that this mutation can be also be identified in patients with CPC, OS, breast cancer and, more recently, neuroblastoma (Giacomazzi et al, 2013; Seidinger et al, 2015; Andrade et al, 2016) . All told, it is likely that TP53 R337H predisposes to the more typical cancers seen in LFS, albeit with a lower penetrance.
Genetic modifiers influencing the phenotype in germline TP53 mutation carriers
The variability in age of onset and type of cancers occurring in TP53 mutation carriers, even those within the same family, has supported the notion that factors other than the germline TP53 mutation influence disease presentation. Indeed, many studies have sought specific genetic modifiers and examined their effect on disease penetrance and expressivity, as well as on the levels or function of mutant TP53. In this regard, a single nucleotide polymorphism (SNP) within the first intron of MDM2 (NM_002392.3:c.14+309T>G; SNP309; rs2279744) has been associated with an earlier age of tumour onset in LFS (Bond et al, 2004; Bougeard et al, 2006; Ruijs et al, 2007) . Bond et al (2004 Bond et al ( , 2006 ) studied 88 individuals with LFS and demonstrated an accelerated age of cancer onset in association with SNP309. Specifically, individuals harbouring the heterozygous G/T or homozygous G/G genotype developed STS an average of 12 years earlier and breast cancer 10 years earlier than those carrying the homozygous wild-type T/T genotype. In LFS patients with STS, the number of primary tumours was also higher in those with SNP309G/T or G/G. Mechanistic studies have revealed that the G allele for SNP309 results in higher levels of MDM2 mRNA and protein, resulting in increased degradation of TP53 and thus defective TP53-mediated apoptosis (Bond et al, 2004 (Bond et al, , 2006 . The early age at cancer onset conferred by MDM2 SNP309 is further amplified by presence of a common polymorphism in codon 72 of TP53 (NM_000546.5 (TP53): c.215C>G ;rs1042522) in which the proline (P) at codon 72 is replaced by arginine (R). Thus, compared to TP53 containing P72, TP53 R72 binds MDM2 with higher affinity, resulting in enhanced degradation. The presence of MDM2 SNP309 and TP53 R72 was shown to have a cumulative effect and associated with earlier age of cancer onset (Malkin, 2011) .
Recently, a second MDM2 polymorphism, denoted SNP285G>C (rs117039649), was reported to be in linkage with the SNP309G allele. In a large study of 195 LFS patients, this haplotype was shown to influence cancer onset with cancers occurring 5 years earlier in those with the MDM2 285-309 G-G haplotype compared to other haplotypes (Renaux-Petel et al, 2014) . In this study, the interaction between this MDM2 haplotype and the TP53 codon 72 polymorphism was not examined. Additional genetic factors have been reported as potential modifiers of the LFS phenotype, including a 16-base pair insertion/duplication in intron 3 of TP53 (rs17878362) (Marcel et al, 2009 ), a SNP within a microRNA known as miR-605 (rs2043556) (Id Said et al, 2016) , and the presence of germline DNA copy number variants (Malkin, 2011) . The extent to which these modifiers reliably and consistently influence LFS phenotype remains to be determined.
To date, there are no reports of genetic modifiers linked specifically to the development of haematopoietic cancers in individuals with LFS.
Genetic testing for LFS
Following the discovery of TP53 as the causative gene in LFS in 1990, there was caution regarding the provision of germline genetic testing because, at the time, there was limited understanding of how genetic test results would influence clinical management and significant concerns regarding the psychological effects associated with a positive test result. With time, however, a better understanding has emerged regarding the natural history of LFS and the possible approaches to tumour surveillance and cancer risk reduction. In addition, studies of the psychological and emotional consequences of testing, while limited, have revealed that adults undergoing LFS testing do not experience long-term adverse psychological consequences (Lammens et al, 2010a) . Accordingly, pre-symptomatic and diagnostic germline TP53 testing are now more widely accepted by families and healthcare providers. Given the clinical and psychological complexities of LFS, it is strongly recommended that genetic testing for this condition be completed by haematologists, oncologists, genetics professionals or other providers who are familiar with this condition and only in the context of pre-and post-test genetic counselling (Malkin, 2011) .
One of the key issues to be contemplated when offering germline TP53 genetic analysis to a patient with leukaemia or MDS is that testing cannot always be performed using a sample of blood. In patients with active disease or positive minimal residual disease (MRD) status, it may be difficult to determine whether an identified mutation is constitutional or originating from circulating neoplastic cells. Indeed, with the increased sensitivity of next generation sequencing, it is now possible to detect mutations present at a frequency of 10% or less. Therefore, presence of a TP53 mutation could reflect germline mosaicism or alternatively, presence of a leukaemic or MDS clone. Saliva samples and cells obtained by buccal swabbing are often considered as alternative sources of DNA for genetic testing. Unfortunately, neoplastic cells may also contaminate these samples. Ideally, testing should involve the analysis of skin fibroblasts obtained from a punch skin biopsy. This procedure is more invasive and requires 6-8 weeks to generate cells for testing; however, it provides the best chances for the most accurate diagnosis.
LFS classification criteria
To facilitate the identification of individuals and families with suspected LFS and provide guidelines for germline TP53 genetic testing, several classification systems have been developed (Table II) . According to the 'classic' and most stringent criteria, LFS is defined by the presence of: (i) a proband with a sarcoma diagnosed before the age of 45 years; (ii) a first degree relative with any cancer before the age of 45 years; and (iii) a first-or second-degree relative with any cancer before the age of 45 years or a sarcoma at any age (Li et al, 1988) . More inclusive classification systems have been created for those families that do not meet classic criteria, but nonetheless exhibit an 'LFS-like' or LFL phenotype. The first was reported by Birch et al (1994) , and includes families in which the proband has: (i) any childhood cancer or a sarcoma, CNS tumour or ACC diagnosed before the age of 45 years; (ii) a first or second degree relative with an LFStype tumour at any age; and (iii) a first or second degree relative with any cancer before the age of 60 years. The second was reported 1 year later (Eeles, 1995) and includes families with two-first or second degree relatives with an LFS tumour at any age. A more recent classification scheme, was put forth by Chompret et al (2001) and revised in 2009 (Tinat et al, 2009) . Although more restrictive than the Birch or Eeles criteria in terms of the cancer types and ages of onset in the proband, the Chompret criteria take into account the fact that some individuals with LFS do not necessarily need a positive family of cancer in order to warrant consideration of germline TP53 testing. The revised Chompret criteria recommend testing for a proband with: (i) an LFS-type tumour diagnosed before the age of 46 years and at least one-first or second degree relative with an LFS-type tumour before the age of 56 years or with multiple primary tumours; (ii) multiple primary tumours diagnosed before the age of 46 years, two of which are LFS component tumours, regardless of the family history; or (iii) an ACC or a CPC at any age, regardless of the family history (Tinat et al, 2009) .
Currently, germline TP53 testing is most commonly considered for individuals meeting classic or Chompret criteria or to any females with early-onset breast cancer who lack a BRCA1 or BRCA2 mutation. As noted above, children with low hypodiploid ALL or any individuals with therapy- Table II . Li-Fraumeni syndrome diagnostic and testing criteria.
Classic LFS criteria (Li et al, 1988) • Proband diagnosed with sarcoma before age 45 years AND first degree relative with a cancer diagnosed before age 45 years AND a first-degree or second-degree relative with any cancer with onset before age 45 years OR a sarcoma at any age • 70% probability of identifying a germline TP53 mutation (Varley, 2003 ) Birch LFL criteria (Birch et al, 1998) • Proband with any childhood cancer, sarcoma, brain tumour or adrenocortical carcinoma with onset less than 45 years of age AND a first-degree relative with either breast cancer, sarcoma, brain tumour, adrenocortical carcinoma or leukaemia with onset at any age AND a first-degree relative with any cancer with onset before 60 years of age • 20-40% probability of identifying a germline TP53 mutation (Varley, 2003) Eeles LFL criteria (Eeles, 1995) • Two first-degree or second-degree relatives with either breast cancer, sarcoma, brain tumour, or leukaemia at any age • 20-40% probability of identifying a germline TP53 mutation (Varley, 2003) 2009 Chompret criteria (Tinat et al, 2009) • Proband with core LFS tumour (premenopausal breast cancer, soft tissue sarcoma, osteosarcoma, brain tumour, leukaemia or adrenocortical carcinoma) before 46 years of age AND at least one-first-degree or second-degree relative with LFS-core tumour (except breast cancer if the proband has breast cancer) before 56 years of age OR with multiple tumours • Proband with multiple tumours (except multiple breast tumours), two of which are core LFS tumour types, first of which had to occur prior to age 46 years • Any patient with adrenocortical carcinoma or choroid plexus tumour irrespective of family history.
• 82-95% sensitivity and 47-58% specificity (Gonzalez et al, 2009a; Tinat et al, 2009; Ruijs et al, 2010) LFL, Li-Fraumeni syndrome-like; LFS, Li-Fraumeni syndrome.
associated leukaemia or MDS also warrant strong consideration, especially when there is a personal or family history of LFS-associated cancers. As might be expected, the chances of finding a germline TP53 mutation differ depending upon the criteria used to guide testing, with about 60-80% of individuals meeting classic and 20-30% meeting Chompret criteria harbouring a germline TP53 mutation (Olivier et al, 2003; Varley, 2003; Mai et al, 2012) . Most LFS mutations are inherited with the frequency of de novo mutations at around 7-20% (Gonzalez et al, 2009b) . Given the observation that a sizable proportion of individuals with an LFS or LFS-like phenotype lack identifiable germline TP53 mutations, it is very likely that other genetic aberrations exist to explain cancer development. These aberrations might include mutations in non-coding regions of the genome that negatively influence TP53 expression or, alternatively, mutations in genes other than TP53 itself. Therefore, families who test negative for germline TP53 mutations, including those presenting with leukaemia as the sole manifestation, should be carefully evaluated and offered testing for other cancer predisposing conditions, where appropriate.
Familial testing for LFS may identify asymptomatic individuals who carry a germline TP53 mutation. Such information has significant health implications and these individuals should be offered surveillance and for women, the possibility of prophylactic mastectomy, as would be done for TP53 mutation carriers who have already developed one or more cancers (Villani et al, 2016) .
For individuals of reproductive age, genetic counselling should be offered to discuss recurrence risks. Parents with an identified germline TP53 mutation can consider prenatal testing, which includes analysing DNA extracted from fetal cells obtained by amniocentesis at 15-18 weeks gestation or by chorionic villus sampling at ten to 12 weeks gestation, as well as pre-implantation genetic diagnosis.
Cancer surveillance in LFS
The goals of cancer surveillance are to improve overall outcomes by enabling the early detection and treatment of tumours. In general, surveillance is best suited for solid neoplasms, where prognosis may be better following complete resection of the presenting tumour. Indeed, such is the case with many LFS-associated solid tumours including certain sarcoma subtypes, glioma, medulloblastoma, CPC and ACC (McBride et al, 2014) . Smaller completely resected tumours may require reduced or even no chemo-or radiation therapy. In theory, this could minimize the risk for therapy-associated second cancers. Although the diversity of cancer types and age at cancer onset make screening in LFS challenging, Villani et al (2016) recently reported that a multi-modal screening protocol is feasible and associated with a significantly improved survival for individuals with LFS. Using what is now referred to as the 'Toronto protocol', these investigators monitored carriers of a germline TP53 mutation using physical examination in conjunction with frequent blood work and imaging studies (Table III) . A total of 40 asymptomatic tumours were detected in 19 (32%) of 59 patients who underwent surveillance, while 61 symptomatic tumours were detected in 43 (88%) of the 49 patients who initially declined surveillance (19 of these subsequently crossed over to the surveillance arm). Notably, the 5-year survival was 88% for those undergoing and 59Á6% for those declining surveillance (Villani et al, 2011) . The results of this study are promising and provide the first evidence in support of the potential survival benefits of surveillance for carriers of germline TP53 mutations. Nonetheless, this screening protocol is not without its limitations, with one patient having false negative and two patients' false positive results. Furthermore, there were a number of incidental findings identified by whole body magnetic resonance imaging (WBMRI; a component of the screening protocol), the majority of which required dedicated follow-up imaging. Currently, several trials are ongoing to further investigate the utility of WBMRI with or without other screening modalities as a means of tumour surveillance in LFS and to identify the optimal types and frequencies of screening procedures (Villani et al, 2016) .
In the report by Villani et al (2016) , two individuals developed AML and two MDS. Only one of these survived: an adult with MDS who chose not to undergo surveillance. Currently, it remains unknown whether surveillance for haematopoietic malignancies confers a medical benefit for those affected with LFS. Nonetheless, consideration should be given to regular monitoring of peripheral blood counts. In addition, patients should undergo periodic physical examinations to evaluate for the signs and symptoms of a haematopoietic cancer, such as fever, pallor, petechiae, easy bruising, lymphadenopathy and hepatosplenomegaly. If any of these are present, or if there are persistent changes in the blood counts from baseline, a bone marrow aspirate and biopsy should be performed.
It is important to recognize the emotional, psychological and financial burdens that frequent screening evaluations create. These tests require multiple visits to the clinic and are fraught with the possibility of false positive results. In a study of high-risk women who were proven germline TP53 mutation carriers and those at 50% risk, Lammens et al (2010b) observed that 90% of participants surveyed believed in the value of surveillance to detecting early stage tumours. Furthermore, 84% stated that surveillance gave them a sense of control and 70% indicated a sense of security. In this study, there were no significant differences in the levels of distress or worry between women who chose and those who did not choose to undergo surveillance as recommended by their health care providers. While limitations exist in terms of sample size, these findings are reassuring. As pertains to children, there is concern that frequent screening may increase anxiety and reduce the quality of life (McBride et al, 2014) . Further research is needed to objectively evaluate these concerns, as children and adolescents are at a formative, yet psychologically vulnerable period in their lives and may require life-long cancer monitoring. 
Recommendations for cancer prevention and treatment
Currently there are limited options for cancer prevention in LFS. Given the high risk for breast cancer development in women with LFS, females harbouring a germline TP53 mutation should be counselled about the option of risk-reducing prophylactic mastectomy (Thull & Vogel, 2004) . For those who develop a breast cancer, mastectomy should be encouraged over lumpectomy to lessen the risks for development of new primary breast cancers or radiation-induced secondary malignancies (Schneider et al, 1993) .
There are no consensus recommendations regarding the acute management of solid cancers in patients with germline TP53 mutations. When possible, it is prudent to reduce exposure to ionizing radiation to help decrease the risk for secondary tumours within the radiation field. Concern also exists regarding the choice of chemotherapeutic agents, particularly alkylating agents, whose use is associated with the possible risk of inducing leukaemia or myelodysplasia (Felix et al, 1996; Schulz et al, 2012; Kamihara et al, 2014) . Regardless of these risks, it is currently recommended that cure of the existing malignancy must remain the top priority.
In terms of LFS-associated leukaemia, the treatment of hypodiploid ALL has been challenging, with survival rates of 50% or less despite the use of intensive chemotherapeutic regimens (Pui et al, 1987; Nachman et al, 2007) . Furthermore, until recently, there were no known prognostic markers to help direct therapy. Mullighan et al (2015) reported that the outcome of children with hypodiploid ALL could be stratified based on the MRD level at the end of leukaemia induction (Mullighan et al, 2015) . In this study, 20 children with hypodiploid ALL, including 12 with the low hypodiploid subtype (only one of whom had a documented germline TP53 mutation) were treated according to the St Jude TOTAL Therapy Studies. Patients with MRD ≥1% after completion of induction were offered the option of allogeneic haematopoietic stem cell transplantation (allo-SCT). Although all 20 patients achieved a clinical remission at the end of induction, only 14 were found to have a negative MRD status. Survival was significantly better for those with negative MRD (85Á5%) versus those with a positive result (44Á4%). The one patient with a germline TP53 mutation experienced a relapse. Although numbers are small, this study suggests that, as with other forms of ALL, MRD serves an important prognostic indicator for childhood hypodiploid ALL, an aggressive and very difficult-to-treat leukaemia subtype.
The published literature as to whether the presence of a germline TP53 mutation confers a poorer prognosis in patients with haematopoietic cancers is limited. Similarly, there is little information regarding the optimal treatment approaches for primary or therapy-related disease in germline TP53 mutation carriers. At present, it is not clear whether treatment regimens should be altered to avoid or lessen exposure to DNA damaging chemotherapeutic agents, as is done with patients who have Fanconi anaemia or Ataxia Telangiectasia. In addition, it remains to be determined whether allo-SCT will improve the outcomes for patients with relapsed or refractory leukaemia. When allo-SCT is being considered, it is important to offer relatives targeted TP53 genetic testing prior to harvesting to avoid the possibility of collecting and inadvertently transplanting TP53 mutation-containing stem cells. Finally, it was recently reported that low hypodiploid ALL cells exhibit activation of Ras and PI3K pathways and are susceptible to inhibition of PI3K and/or mTOR signalling (Holmfeldt et al, 2013) . These data suggest that therapeutic targeting of these pathways could prove beneficial as a treatment for patients with low hypodiploid ALL, positive MRD and/or recalcitrant disease.
Conclusions and future directions
Much has been learned about TP53 and its central role in maintaining genomic stability and suppressing malignant transformation. Nonetheless, it is impossible to predict with certainty when and which TP53 mutation carriers will develop a first or subsequent cancer, how to delay or prevent these cancers from occurring, and how to treat them most effectively. Future collaborative studies that integrate clinical, genomic and biological information will undoubtedly shed light onto this challenging cancer predisposition syndrome. Towards this end, the increased application of high throughput molecular approaches will provide new insights into the genetic and epigenetic events that drive tumour formation. This information may also help to explain the diverse manifestations of LFS, including the differences in disease penetrance, heterogeneity of tumours formed and the disparity in age of cancer onset among germline TP53 mutation carriers. A better understanding of how these factors influence disease phenotype may permit the development of individualized monitoring protocols. Finally, with the advent of genome editing and induced pluripotent stem cell technologies, it is now possible to generate and possibly reverse specific germline TP53 mutations. These technologies will allow for the modelling of tumour formation in LFS and the dissection of critical cellular pathways and processes that can be then targeted to treat or even prevent tumour formation. Looking to the future, there is no doubt that LFS will remain as a paradigm for the exploration and understanding of TP53-associated solid and blood cancers and heritable cancer risk.
